TIAA Trust National Association Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

TIAA Trust National Association cut its stake in Pfizer Inc. (NYSE:PFE) by 9.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 405,240 shares of the biopharmaceutical company’s stock after selling 41,107 shares during the quarter. TIAA Trust National Association’s holdings in Pfizer were worth $10,751,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the 4th quarter worth $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer during the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the fourth quarter worth about $28,000. Noble Wealth Management PBC purchased a new position in Pfizer during the fourth quarter worth about $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer in the 4th quarter valued at approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on PFE shares. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Price Performance

Shares of PFE opened at $25.56 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a market cap of $144.96 billion, a P/E ratio of 18.13, a PEG ratio of 0.64 and a beta of 0.61. The firm’s 50 day moving average price is $26.14 and its 200 day moving average price is $27.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period last year, the firm earned $0.10 earnings per share. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.